21 Hrs
Source:
اقتصاد سكاي نيوز عربية
Source: اقتصاد سكاي نيوز عربية
21 Hrsاقتصاد سكاي نيوز عربية
Source: اقتصاد سكاي نيوز عربية
21 HrsReady to play
Ready to play
German company Merck plans to acquire British company Silence Therapeutics for $1.1 billion, in a move to expand its capabilities in treating rare diseases, especially through the third phase of clinical trials for the targeted drug Dvesiran, intended to treat rare polycythemia vera. The deal, estimated at an 82% increase over the average stock price of the past month, is expected to be completed in the first quarter of 2027 and will be financed by the company through new loans. This acquisition reflects Merck’s strategy to strengthen its presence in the fields of specialized treatments and rare diseases.
Notice: This Is an AI-Generated Summary
Comments (0)